1. Infection

Infection

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-148457
    Avacincaptad pegol 1613641-69-2
    Avacincaptad pegol (Izervay) is a selective inhibitor targeting complement component C5, and is a pegylated ribonucleic acid aptamer. Avacincaptad pegol inhibits the cleavage of C5 into pro-inflammatory C5a and C5b, which forms the membrane attack complex (C5b-9), thereby reducing inflammatory cell recruitment and retinal cell damage. Avacincaptad pegol can slow the growth of geographic atrophy (GA) lesions and reduce the risk of persistent vision loss. Avacincaptad pegol can be used in research of geographic atrophy associated with age-related macular degeneration (AMD) and has been approved by the FDA.
    Avacincaptad pegol
  • HY-B1159S
    Nitroxoline-d4 98%
    Nitroxoline-d4 is the deuterium labeled Nitroxoline. Nitroxoline is an antibiotic that has proven to be very effective at combating biofilm infections. Nitroxoline functions by chelating Fe2+ and Zn2+ ions from the biofilm matrix.
    Nitroxoline-d4
  • HY-124618A
    FGI-106 tetrahydrochloride 1149348-10-6 99.68%
    FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola, Rift Valley and Dengue Fever viruses with EC50s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC50s of 200 nM and 150 nM, respectively.
    FGI-106 tetrahydrochloride
  • HY-126323B
    TCMDC-135051 hydrochloride 2705545-47-5 98.17%
    TCMDC-135051 hydrochloride is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 hydrochloride prevents trophozoite-to-schizont transition, disrupts transcription and reduces transmission to the mosquito vector. TCMDC-135051 hydrochloride has antiparasiticidal activity (EC50=320 nM).
    TCMDC-135051 hydrochloride
  • HY-14956
    Nemonoxacin 378746-64-6 99.77%
    Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
    Nemonoxacin
  • HY-15256
    Faldaprevir 801283-95-4 98.58%
    Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with Ki values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC50 values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection.
    Faldaprevir
  • HY-B0159
    Balofloxacin 127294-70-6 98.26%
    Balofloxacin (Q-35) is an orally active fluoroquinolone antibiotic with broad-spectrum antibacterial activity against gram-negative, gram-positive, and anaerobic bacteria. Balofloxacin can be used for the research of respiratory, intestinal, and urinary tract infections.
    Balofloxacin
  • HY-103643
    Fumagillol 108102-51-8 98.0%
    Fumagillol is a direct precursor of fumagillin. Fumagillin, as an antimicrobial agent, is a potent and selective inhibitor of angiogenesis.
    Fumagillol
  • HY-147263
    Dovramilast 340019-69-4 99.66%
    Dovramilast (CC-11050) is an orally active phosphodiesterase 4 (PDE4) inhibitor and can reduce the inflammatory response and improves Isoniazid (HY-B0329)-mediated bacillary clearance from the lungs. Dovramilast, as an adjunct, is used for the research of tuberculosis (TB).
    Dovramilast
  • HY-147358
    Yimitasvir diphosphate 1959593-63-5 99.42%
    Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection.
    Yimitasvir diphosphate
  • HY-168738
    Limnetrelvir 2923500-04-1 99.81%
    Limnetrelvir (ABBV-903) is a MPro inhibitor. Limnetrelvir could be used in antiviral research.
    Limnetrelvir
  • HY-P99177
    Enibarcimab 2305638-98-4 99.68%
    Enibarcimab is a humanized, non-neutralizing monoclonal antibody targeting adrenomedullin (ADM). Enibarcimab binds to the N-terminus of ADM, retains ADM in the circulation, and mobilizes interstitial ADM to increase the level of active bio-ADM, ultimately stabilizing blood vessels. Enibarcimab can be used in research related to septic shock and acute heart failure.
    Enibarcimab
  • HY-P99346
    Regdanvimab 2444308-95-4
    Regdanvimab (CT-P59) is a human monoclonal antibody that targets the receptor-binding domain of SARS-CoV-2 spike protein, blocking interaction with ACE2 for viral entry. Regdanvimab can be used for the research of COVID-19.
    Regdanvimab
  • HY-P99435
    Amubarvimab 2509447-07-6
    Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants.
    Amubarvimab
  • HY-P99490
    Burfiralimab 2460809-80-5
    Burfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
    Burfiralimab
  • HY-119123A
    Voxvoganan trihydrochloride 99.75%
    Voxvoganan (LTX-109) trihydrochloride, a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan trihydrochloride can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA.
    Voxvoganan trihydrochloride
  • HY-145569A
    Fipravirimat dihydrochloride 2442512-14-1 99.70%
    Fipravirimat dihydrochloride is a potent HIV-1 inhibitor. Fipravirimat dihydrochloride has the potential for HIV and AIDS research.
    Fipravirimat dihydrochloride
  • HY-19964
    Potassium clavulanate cellulose 98.0%
    Potassium clavulanate cellulose (Potassium clavulanate:cellulose (1:1)) is a mixture of potassium clavulanate and cellulose, is a bacterial β-lactamase inhibitor. Clavulanate potassium is a form of Clavulanic acid. Clavulanate potassium fights bacteria that resistant to penicillins and other antibiotics. Potassium clavulanate with the combination of amoxicillin can be used for the research of different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin.
    Potassium clavulanate cellulose
  • HY-10882S
    Clotrimazole-d5 1185076-41-8 99.47%
    Clotrimazole-d5 is the deuterium labeled Clotrimazole. Clotrimazole is an imidazole derivative, an antifungal compound and is a CYP (cytochrome P450) inhibitor. Clotrimazole has antibacterial activity.
    Clotrimazole-d5
  • HY-14648S
    Dexamethasone-d5 358731-91-6 99.23%
    Dexamethasone-d5 is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
    Dexamethasone-d5
Cat. No. Product Name / Synonyms Application Reactivity